Robotic surgery’s market leader has had a rough start to 2026, but our model sees the pullback as an opportunity. Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) trades at $482.22 after a 14.86% year-to-date decline, even as Q1 procedure growth and da Vinci 5 adoption continue to accelerate.
Our 24/7 Wall St. price target for Intuitive Surgical is $615.93, implying meaningful upside over the next 12 months.
24/7 Wall St. Price Target Summary
| Metric | Value |
|---|---|
| Current Price | $482.22 |
| 24/7 Wall St. Price Target | $615.93 |
| Upside | 27.73% |
| Recommendation | BUY |
| Confidence | 90% |
A Sell-Off That Outran the Fundamentals
Shares are down 5.1% over the past year and sit roughly 20% below the 52-week high of $603.88. The stock has stabilized recently, gaining 2.77% over the past week, helped by a strong Q1 2026 print on April 21.
Intuitive delivered non-GAAP EPS of $2.50 versus a $2.11 consensus, and revenue of $2.77 billion, up 22.96% YoY. Operating income jumped 47.95%, and the company placed 431 da Vinci systems, including 232 da Vinci 5 units. That marks four straight EPS beats.
The Case for $649 and Higher
Bulls point to da Vinci 5, which now has an installed base of 1,500 systems and is driving U.S. utilization growth of 4%, higher than Xi. CEO Dave Rosa noted “da Vinci 5 utilization continues to exceed that of da Vinci Xi”.
Single Port procedures grew 68% YoY, and Ion procedures climbed 39%, supported by a Mayo Clinic study showing 79% diagnostic yield in lung lesion biopsy. Our bull case price is $649.08, a 34.6% total return.
The Risks Worth Watching
The bear case starts with valuation. ISRG trades at a P/E of 58 and EV/EBITDA of 42. Procedure growth is decelerating to 13.5% to 15.5% in 2026, down from 18% in 2025.
Tariffs on Mexico, Germany, and China sourcing add roughly 1% revenue drag, GLP-1 adoption pulled bariatrics down 10%, and China faces policy-driven pricing pressure.
Insider activity has been net selling, though it appears largely tied to scheduled vesting. Bulls would counter that gross margin actually expanded to 67.8%, and da Vinci 5 contribution margins are now comparable with Xi. Our bear case price is $546.67, still above today’s price.
Our Take on Intuitive Surgical Here
My read: the 24/7 Wall St. price target of $615.93 with 90% confidence reflects a high-quality compounder trading at a 20% discount to its 52-week high while still posting 23% revenue growth. The bull thesis stays intact if da Vinci 5 placements stay above 230 per quarter and tariff drag holds at 1%. The setup weakens if procedure growth slips below 13% or hospital capex tightens materially.
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $615.93 |
| 2030 | $981.22 |
Outer-year projections for 2027-2029 are not separately modeled; our framework anchors on the 12-month target and a 2030 endpoint, assuming mid-teens procedure growth, modest multiple compression, and continued buybacks. Significant variance could come from da Vinci 5 international ramp, telesurgery commercialization, or tariff escalation.
Top Gaining Stocks
Top Losing Stocks